Literature DB >> 2230265

Bacterial infections in patients with visceral leishmaniasis.

T M Andrade1, E M Carvalho, H Rocha.   

Abstract

Bacterial infections are often seen in patients with visceral leishmaniasis. To determine the incidence of such infection and the more common infectious agents, 30 consecutive patients with visceral leishmaniasis were followed throughout hospitalization. There were 24 episodes of bacterial infection in 18 patients (60%). The incidence of bacterial infections in these patients was 22.2/1000 days of admission. The proportion of patients becoming infected by time was significantly greater in the visceral leishmaniasis group than in controls (P less than .01). The skin, respiratory tract, and middle ear were the most common sites of infection, and Pseudomonas aeruginosa and Staphylococcus aureus were the most common agents. Low-grade-virulence bacteria (e.g., Serratia and Providencia species) were also isolated from some cases. Bacterial infections (mainly nosocomial) in patients with visceral leishmaniasis tend to be severe and can cause death. When bacterial infection is suspected in these patients, empiric antibiotic therapy should be started immediately, including coverage for P. aeruginosa and S. aureus, after appropriate diagnostic procedures are taken.

Entities:  

Mesh:

Year:  1990        PMID: 2230265     DOI: 10.1093/infdis/162.6.1354

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.

Authors:  Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

2.  Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.

Authors:  R Badaró; C Nascimento; J S Carvalho; F Badaró; D Russo; J L Ho; S G Reed; W D Johnson; T C Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

3.  [Kala azar - Lethal course of visceral leishmaniasis. Synchronous infection with Leishmania donovani/infantum complex and Leishmania major in a patient after Mediterranean vacation].

Authors:  C Posch; J Walochnik; A Gschnait; H Feichtinger; K Rappersberger
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

4.  Unusual presentations of Visceral leishmaniasis.

Authors:  Rajniti Prasad; Sunil Muthusami; Nisha Pandey; Vijay Tilak; Jyoti Shukla; Om Prakash Mishra
Journal:  Indian J Pediatr       Date:  2009-05-27       Impact factor: 1.967

5.  Natural autoantibodies, IgG antibodies to tetanus toxoid and CD5+ B cells in patients with Mediterranean visceral leishmaniasis. The Leishmania Study Group.

Authors:  H Louzir; L Belal-Kacemi; A Sassi; D Laouini; R Ben Ismail; K Dellagi
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

6.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.

Authors:  Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida
Journal:  PLoS Negl Trop Dis       Date:  2016-01-27

7.  Early clinical manifestations associated with death from visceral leishmaniasis.

Authors:  Valdelaine Etelvina Miranda de Araújo; Maria Helena Franco Morais; Ilka Afonso Reis; Ana Rabello; Mariângela Carneiro
Journal:  PLoS Negl Trop Dis       Date:  2012-02-07

8.  Low CXCL13 expression, splenic lymphoid tissue atrophy and germinal center disruption in severe canine visceral leishmaniasis.

Authors:  Joselli S Silva; Alan C Andrade; Claudia C Santana; Leina Q Santos; Camila I de Oliveira; Patrícia S T Veras; José Vassallo; Washington L C dos-Santos
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

9.  The price of the CD27-CD70 costimulatory axis: you can't have it all.

Authors:  Martijn A Nolte; René A W van Lier
Journal:  J Exp Med       Date:  2006-10-23       Impact factor: 14.307

10.  Inflammation and structural changes of splenic lymphoid tissue in visceral leishmaniasis: a study on naturally infected dogs.

Authors:  C C Santana; J Vassallo; L A R de Freitas; G G S Oliveira; L C Pontes-de-Carvalho; W L C dos-Santos
Journal:  Parasite Immunol       Date:  2007-06-28       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.